WhatsApp
backNews Article

Molbio Diagnostics Reports INR 667 Crores Revenue for H1 FY27 with Expansion Plans in Veterinary Diagnostics and New Product Launches

EBITDA at INR 153 crores with 23% margin; net cash position achieved by September 2026 amid new product validations and export growth

Molbio Diagnostics Limited reported a consolidated revenue of INR 667 crores for the first half of fiscal year 2027, close to last year's INR 680 crores. The company discussed expansion into new veterinary diagnostic products and new multiplexing platforms, alongside ongoing export growth and R&D developments. EBITDA was INR 153 crores with a 23% margin, and PAT was INR 60 crores influenced by acquisition costs. The company improved to a net cash position by September 2026.

11 Nov 2026|MOLBIO-0.77%
Molbio Diagnostics LimitedMOLBIOEarnings Call Transcript

Molbio Diagnostics Limited

Earnings Call Transcript

Molbio Diagnostics Limited announced consolidated revenue of INR 667 crores for the first half of fiscal year 2027, slightly below the previous year's INR 680 crores, due to delayed government contract renewals. The company is advancing new veterinary diagnostic products and multiplex testing platforms, aiming to expand in exports and new markets.

The revenue softness compared to last year was attributed to a one-month delay in renewing a government rate contract, which the company expects to recover in the coming months.

Molbio Diagnostics sold 559 diagnostic devices and nearly 95 lakh kits during the first half of FY27, with exports contributing INR 120 crores to revenue.

Earnings before interest, tax, depreciation and amortization (EBITDA) stood at INR 153 crores, representing 23% of total revenue, including a INR 15 crore EBITDA loss related to the OptraSCAN subsidiary acquisition.

Profit after tax (PAT) was INR 60 crores, impacted by additional interest costs and intangible asset amortization from OptraSCAN acquisition.

The company has improved its net cash position as of September 2026, moving from a net debt of INR 57 crores in March 2026 due to efficient receivables and inventory management, with 77 days receivable and 1.2 times inventory turnover ratio for the trailing twelve months period ending H1 FY27.

Highlights

  • Consolidated H1 FY27 revenue of INR 667 crores against INR 680 crores in H1 FY26, slightly lower due to contract renewal delays.
  • EBITDA of INR 153 crores with 23% margin, including INR 15 crores EBITDA loss from OptraSCAN acquisition.
  • PAT at INR 60 crores, influenced by finance cost and amortization from recent acquisition.
  • Export revenue contributed INR 120 crores in H1 FY27.
  • Sold 559 devices and 94.7 lakh kits in the first half of FY27.
  • Net cash position achieved as of September 2026, improving interest income and reducing expenses compared to earlier quarters.

Key Data Snapshot

Consolidated Revenue H1 FY27INR 667 crores
Consolidated Revenue H1 FY26INR 680 crores
Export Revenue H1 FY27INR 120 crores
EBITDA H1 FY27INR 153 crores
EBITDA Margin H1 FY2723%
EBITDA Loss due to OptraSCANINR 15 crores
PAT H1 FY27INR 60 crores
Devices Sold H1 FY27559
Kits Sold H1 FY2794.7 lakh
Net Cash Position DateSeptember 2026
Receivable Days Trailing 12 Months77 days
Inventory Turnover Trailing 12 Months1.2 times
Net Debt Position March 2026INR 57 crores

What happened

  • Molbio Diagnostics Limited disclosed its consolidated financial results for the quarter and half year ended September 30, 2026.
  • Reported consolidated revenue was INR 667 crores for H1 FY27, just below last year's INR 680 crores.
  • EBITDA for the period was INR 153 crores representing 23% margin, with a loss contribution from subsidiary OptraSCAN.
  • Profit after tax was INR 60 crores, impacted by acquisition-related costs and financing expenses.
  • The company achieved a net cash position by September 2026.
  • Sales for H1 FY27 included 559 devices and 94.7 lakh kits with exports accounting for INR 120 crores of revenue.

Key details

  • Revenue was affected by a one-month delay in renewing government rate contracts, which is expected to be recouped in later periods.
  • The business typically sees 40% of revenue in the first half and 60% in the second half of the fiscal year.
  • The company is expanding its geographic footprint and increasing export-oriented activities.
  • Molbio is advancing several new veterinary diagnostic products expected to market in fiscal 2028.
  • R&D pipeline includes new product validations and launches planned in the next 3-4 months.
  • Molbio is developing multiplexing platforms such as Trueamp® and Truecyte® addressing hospital and clinical testing needs respectively.

Funding and capital details

  • The OptraSCAN acquisition, which became a subsidiary in H2 FY26, contributed to a loss of INR 15 crores in EBITDA and affected PAT due to amortization and increased interest expense.
  • Efficient collections and working capital management improved receivable days to 77.
  • Inventory turnover remained stable at 1.2 times.
  • The company moved from net debt of INR 57 crores in March 2026 to a net cash position by September 2026, resulting in higher interest income and lower interest expenses in Q2 FY27 compared to Q1.

Strategic context

  • Molbio Diagnostics is expanding into veterinary applications leveraging existing X-ray and Truenat platforms, with five new veterinary assays in development.
  • Plans include growing export sales, diversifying product lines, and entering new verticals such as veterinary diagnostics and multiplex testing.
  • New product platforms like Trueamp® will enable multiple disease testing on a single sample, targeting hospitals and laboratory networks worldwide.
  • Truecyte® will deliver advanced diagnostics including CBC counts and cell morphology at the point of care.

More News on Earnings Call Transcript

View all

Latest corporate announcements and market updates in Earnings Call Transcript.

View all news
Molbio Diagnostics Reports INR 667 Crores Revenue for H1 | Stockk News